Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news



To view this News Article

Similar stories

Naomi Moris (left) and Ben Schumann (right)

Group Leaders Naomi Moris and Ben Schumann have been awarded European Research Council (ERC) grants for projects that will provide new insights into cell biology and early developm… More...

Emma Wall, Senior Clinical Research Fellow at the Crick and UCLH, has won the prestigious 2022 Sir David Cooksey Prize i… More...

Misty mornings and navigating a new electronic age- after recently retiring as Head of Library and Information Services … More...

Congratulations to Crick Group Leader Samra Turajilic, who has been awarded this year's ESMO Award for Translational Res… More...

Have your say


Contact us

The Francis Crick Institute
1 Midland Road

This website is powered by